Month: April 2021

PRFoodsi 2020/2021. aasta kolmanda kvartali auditeerimata esialgne konsolideeritud käive oli 14,15 miljonit eurot langedes eelmise aasta sama perioodiga võrreldes 23,5% (3kv 2019/2020: 18,49 miljonit eurot), sealhulgas müügilangus hulgimüügis 56,1% ja HoReCa sektoris 45,6%, kusjuures jaekettides oli müügitõus 9,8%. Indrek Kasela, PRFoods juhataja kommentaar: „Nagu oli eeldada, siis HoReCa ja hulgimüük on ikka madalseisus tingituna COVID piirangutest neis sektorites. Samas oleme väga rahul, et meie käive on kasvanud ligi 10% jaekettides, Eestis koguni üle 22% aasta baasil. Samuti on näha turgude taastumist, käesoleva aasta märtsi käive oli juba sama kui eelmise aasta märtsis. Suurem mõju on olnud lõhe hinna langus maailmaturul. Meie värske kala keskmine müügihind viimases kvartalis oli 6,1 eurot kilo kohta võrreldes 7,3 eurot kilo kohta...

New York, NY, April 11, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Global Arena Holding, Inc. (the “Company”) (OTC Markets: GAHC), a growth oriented, acquisition minded company, focused on specific niche markets offering exponential growth — is pleased to announce that the Company has filed its 10-K, and is excited to share a few highlights which will support management efforts at assisting its subsidiary, Global Election Services, Inc. (“GES”), further its expansion into government elections. Management reported that revenues for the 12 months ended December 31, 2020 were $641,629, compared to $477,773 for the 12 months ending 2019 – a roughly 34% increase for the period. Management also reported $308,223 in ‘Deferred Revenue’ for the year ending December 31, 2020; expected to be earned during 2021.  For the 12 months ending...

Singapore, April 8, 2021 — In a bid to expand its ecosystem, leading decentralized exchange MDEX has integrated Binance Smart Chain (BSC), officially completing the deployment today April 8 at 8.30 PM (UTC + 8). Five seconds after integration, MDEX reports a TVL (Total Value Locked) of more than USD 0.5 billion. The BSC integration includes functionality in liquidity mining, single token staking, transaction mining and cross-chain asset services. Users can now use the MDEX Bridge to realize cross-chain interoperability between Heco (Huobi Eco-Chain), and BSC. BSC and Heco Solve Issues of Congestion and High Fees on Ethereum According to MDEX CTO Sky, after Heco, BSC integration was always the plan. “Like Heco, BSC was developed to target the congestion and high fees on the Ethereum network,” states Sky. “Both are also supported by...

Steve Muehler, the Founder & Managing Member of the Steve Muehler Portfolio of Companies, today announced the long-delayed return of Steve Muehler’s “Corner of Main Street & Wall Street” will finally return to YouTube and Podcast starting August 11th, 2021. According to the Statement released by Steve Muehler earlier today: “We were all hyped up and ready to go in June of last year with the return of ‘Corner of Main Street & Wall Street’, after what was supposed to be a short delay for the whole ’14-Days to Stop the Spread’. But as time went on and the whole COVID-19 thing really took over the world, we had to put ‘Corner of Main Street & Wall Street’ on the backburner for a bit while things played out. Before you know it, it is the end of 2020, and we talked about a January 2021 re-start date. Then the Christmas surge...

TORONTO, April 10, 2021 (GLOBE NEWSWIRE) — SUBVERSIVE ACQUISITION LP (TSX: SVX.U, NEO: SVX.U, OTCQX: SBVRF) (“SVX”) announced today that closing of its qualifying transaction to combine with InterCure Ltd. (dba Canndoc) (TASE: INCR), Israel’s leading cannabis company, is expected to occur as soon as practicable after the outstanding conditions to closing are met, which SVX expects to be on or before April 20, 2021. About SVX Subversive Acquisition LP is a limited partnership established under the Limited Partnerships Act (Ontario) formed for the purpose of effecting, directly or indirectly, an acquisition of one or more businesses or assets, by way of a merger, amalgamation, arrangement, equity exchange, asset acquisition, equity purchase, reorganization, or any other similar business combination involving SVX that will qualify...

New York, NY, April 10, 2021 (GLOBE NEWSWIRE) — (GTII:OTCQB) Global Tech Industries Group, Inc. (OTCQB: GTII) (“GTII” or the “Company”), www.gtii-us.com, a Nevada corporation announced on April 9, 2021, that the Company had engaged Alt5 Sigma, Inc. to provide the platform for creating NFTs for its upcoming art assets, as well as future assets requiring tokenization. During their discussions, both companies recognized that a unique synergy may exist between the two companies that warranted further exploration. Both sides believe that a corporate structure combining GTII and Alt5 Sigma could be extremely and mutually beneficial to both companies’ shareholders. As such, the parties have entered into a non-binding Letter of Intent to explore the options for such a business combination, and attempt to arrive at an agreement that is beneficial...

SASKATOON, Saskatchewan, 10 avr. 2021 (GLOBE NEWSWIRE) — Cameco (TSX: CCO; NYSE: CCJ) a annoncé aujourd’hui son intention de relancer la production en avril dans sa mine d’uranium de Cigar Lake, située dans le nord de la Saskatchewan. La production à Cigar Lake a été interrompue temporairement en décembre 2020 en raison de risques croissants posés par la pandémie de coronavirus (COVID-19). À cette période, le nombre de travailleurs disponibles dans les zones critiques diminuait en raison de la pandémie, du fait du nombre plus grand de personnes écartées ou résidant dans des communautés soumises à des restrictions de voyage liées à la pandémie. « Notre priorité absolue est la sécurité de nos travailleurs, de leurs familles et des communautés, a déclaré le président et chef de la direction de Cameco, Tim Gitzel. Au cours...

– CFT7455 Demonstrated High Cereblon Binding Affinity and Rapid, Deep IKZF1/3 Degradation Enabling Activity across a Panel of Multiple Myeloma Cell Lines Including IMiD-Resistant Models – – CFT7455 Promotes Sustained Degradation of IKZF1/3 and Durable Anti-tumor Response, Including Regressions in an IMiD-Insensitive Myeloma Tumor Xenograft Model – – CFT7455 Phase 1/2 Trial in Multiple Myeloma and Non-Hodgkin Lymphomas On Track for 1H 2021 Initiation – WATERTOWN, Mass., April 10, 2021 (GLOBE NEWSWIRE) — C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today presented preclinical data for CFT7455, the Company’s lead program, a MonoDACTM degrader targeting IKZF1/3 for the treatment of hematologic...

SAN FRANCISCO, April 10, 2021 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today announced that it will host a conference call to discuss the recent publication by Novitas Solutions (“Novitas”) of rates applicable to the Current Procedural Terminology (CPT) codes 93243 and 93247. On April 10, 2021, Novitas published updated reimbursement rates for codes 93243 and 93247 at $103 and $115, respectively. The updated rates are retroactive to January 1, 2021 and replace rates initially published on January 29, 2021. iRhythm is assessing the impact of the updated Novitas rates on its business and will provide comments on a conference call on April 12, 2021. Webcast and Conference Call InformationiRhythm will host a conference call...

ZN-c3 demonstrated single agent activity, generating Exceptional Responses in a range of heavily pre-treated solid tumors ZN-c3 was safe and well-tolerated Identified recommended Phase 2 dose for ZN-c3 to be 300 mg QD with continuous dosing Announces plan to start Phase 1/2 osteosarcoma trial in Q3 2021 Company to host webcast event with key opinion leaders on Monday, April 12 at 4:00 p.m. EDT NEW YORK and SAN DIEGO, April 10, 2021 (GLOBE NEWSWIRE) — Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced initial efficacy and safety data from the Phase 1 dose-escalation portion of its ongoing Phase 1/2 clinical trial of ZN-c3 in patients with advanced solid tumors...